Vir Biotechnology, Inc. Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
Vir Biotechnology, Inc. (VIR) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 0 shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2024-02-26
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2022-09-30 was 0.00 shares.
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2022-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2021-09-30 was 0.00 shares.
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for the quarter ending 2021-06-30 was 12.97K shares.
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2023 was 0.00 shares.
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2021 was 3.23K shares.
- Vir Biotechnology, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2020 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 3 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 6 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 9 month | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-26 | |||
| 2022-12-31 | 0.00 shares 10-K · filed 2024-02-26 | |||
| 2022-09-30 | 0.00 shares 10-Q · filed 2022-11-03 | 0.00 shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 0.00 shares 10-Q · filed 2022-08-09 | 0.00 shares 10-Q · filed 2022-08-09 | ||
| 2021-12-31 | 3.23K shares 10-K · filed 2024-02-26 | |||
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-03 | 4.32K shares 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 12.97K shares 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | 0.00 shares 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |